Caribou Biosciences, Inc. (CRBU) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Number of Patients in the B Cell Maturation Antigen-Negative Cohort Treated at the Recommended Dose for Expansion | 12.00 | FY2026-Q1 |
| Number of Patients Treated in the CaMMouflage Phase 1 Dose Escalation Portion | 48.00 | FY2026-Q1 |
| Proof-of-Concept Cohort Size for CD19-Targeted Therapy Relapsed Patients | 10.00 | FY2025-Q1 |
Back to CRBU overview · CRBU earnings · CRBU holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.